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Summary
 
Activation of Ras GTPases is a conserved feature of antigen receptor signaling, including
Fc
 
e
 
R1 activation of mast cells. Antigenic cross-linking of the Fc
 
e
 
R1 on mast cells results in se-
cretion of allergic mediators and induction of immediate early and cytokine genes. Here we
examine the role of Ras in coupling the Fc
 
e
 
R1 to transcriptional regulation. The transcription
factors Elk-1, an immediate early gene regulator and the nuclear factor of activated T cells
(NFAT), in the context of the IL-4 gene, are identified as Ras targets in mast cells. Ras medi-
ates diverse effects via its diverse effector pathways, which may include other members of the
Ras GTPase family such as RhoA and Rac-1. We observe that Elk-1 and NFAT are targeted
by distinct Ras effector pathways in mast cells. Activation of the “classical” Ras/Raf-1/MEK/
ERK cascade is necessary and sufficient for Fc
 
e
 
R1 induction of Elk-1. Ras function is re-
quired, but not sufficient for Fc
 
e
 
R1 induction of NFAT. However, activation or inhibition of
Ras markedly shifts the antigen dose-response for Fc
 
e
 
R1 induction of NFAT. The effector
pathway for Ras activation of NFAT is not Raf-1/MEK. We identify that the Rac-1 GTPase
is critical in Fc
 
e
 
R1 regulation of NFAT, acting either in parallel with or as an effector of Ras.
These data place Ras in a crucial position in mast cells, regulating disparate nuclear targets.
Moreover, we identify that two GTPases, Ras and Rac-1, are important regulators of NFAT,
and therefore of cytokine expression in mast cells.
 
A
 
ntigenic cross-linking of the high affinity receptor for
IgE (Fc
 
e
 
R1) on mast cells results in expression of in-
flammatory function (1). In addition to the release of in-
flammatory mediators from cytoplasmic granules, there is a
significant nuclear component to the activation of mast
cells after Fc
 
e
 
R1 ligation. Expression of various genes is in-
duced, notably leading to de novo synthesis of cytokines
such as IL-4, -6, GM-CSF, and TNF
 
a
 
 (2).
The Fc
 
e
 
R1 complex is tetrameric, comprised of 45-kD
 
a
 
 and 30-kD 
 
b
 
 chains and a homodimer of two disulfide-
linked 10-kD 
 
g
 
 chains (3). Antigenic cross-linking of re-
ceptor-bound IgE results in aggregation of Fc
 
e
 
R1 complexes
in the plane of the plasma membrane and rapid activation
of cytoplasmic protein tyrosine kinases (PTKs)
 
1
 
 (4). Immu-
noreceptor tyrosine-based activation motifs present in
Fc
 
e
 
R1 
 
b
 
 and 
 
g
 
 couple the receptor to the src family PTK
p56lyn and to p72syk (3). Fc
 
e
 
R1-associated PTKs activate a
number of effector pathways which together control mast cell
function. These include PLC
 
g
 
1 activation and subsequent
generation of inositol polyphosphate and diacylglycerol
second messengers (5, 6). These, in turn, modulate intra-
cellular Ca
 
2
 
1
 
 levels and protein kinase C (PKC) activation,
respectively. There are defined roles for Ca
 
2
 
1
 
 and PKC sig-
nals in Fc
 
e
 
R1 regulation of exocytosis (7, 8), and a Ca
 
2
 
1
 
/
calcineurin dependent pathway is known to be important
in the induction of a number of cytokine genes (2, 9).
Our previous work has shown that in addition to Ca
 
2
 
1
 
/
PKC signals, Fc
 
e
 
R1-regulated PTKs are coupled to effec-
tor pathways via the adaptor molecule Grb2 (10). Grb2
forms protein complexes through interactions of its SH2
and SH3 domains with molecules which may be substrates
for receptor-associated PTKs (11). One Grb2 effector mol-
ecule in the mast cell is Sos, the mammalian homologue of
the 
 
Drosophila
 
 “Son of Sevenless” protein (10). Sos is a gua-
nine nucleotide exchange factor that promotes GTP-load-
ing, and hence activation of the GTPase Ras and its effec-
tor pathways. Studies in various systems have placed Ras
in a critical position regulating diverse cellular processes
through its regulation of kinase cascades with transcription
factor targets.
 
1
 
Abbreviations used in this paper:
 
 CAT, chloramphenicol acetyl transferase;
CN, calcineurin; CsA, cyclosporin A; dn, dominant inhibitory; MAP,
mitogen-activated protein; MEK, Erk-activating kinase; NFAT, nuclear
factor of activated T cells; PKC, protein kinase C; PTK, protein tyrosine
kinase.
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It is recognized that Ras is able to activate multiple effec-
tor signaling pathways. An effector pathway mediated by the
Raf-1 serine/threonine kinase has been extensively charac-
terized in numerous systems (12). Raf-1 is recruited to the
plasma membrane by active Ras.GTP. This recruitment re-
sults in Raf-1 activation and subsequent activation of the
mitogen-activated protein (MAP) kinases Erk1 and Erk2
by the Erk-activating kinases (MEKs). Like the B and T
cell antigen receptors, the Fc
 
e
 
R1 activates the Ras/Raf-1/
Erk cascade, but its importance in antigen receptor signal-
ing is not clear. Moreover, studies of the role of Ras in reg-
ulating fibroblast transformation have concluded that the
Raf-1/MEK pathway does not mediate all Ras effector
functions (13). Similarly, in T lymphocytes, the Raf-1/MEK
pathway has been shown to mediate Ras effects on positive
selection of thymocytes but apparently is not required for
Ras control of T cell proliferative responses (14). Alterna-
tive effectors for Ras are less defined than the “classical”
Raf-1/MEK/Erk cascade, but include the Ras GTPase ac-
tivating proteins (Ras-GAPs) (15), PtdIns-3
 
9
 
 hydroxyl ki-
nase (16), and GDS proteins for the GTPase Ral (17).
There is also a consensus that Ras responses are coupled to
signaling networks mediated by Rho family GTPases such
as Rac-1, CDC42, and RhoA (18, 19). The role of these
Rho-family GTPases in antigen receptor responses is not
well characterized, but there is an increasing awareness
from both biochemical and genetic analyses that these mol-
ecules will have important functions in the immune system.
Vav, which is one of the immediate substrates for PTKs as-
sociated with antigen receptor complexes (20), has a do-
main homologous to Dbl, a guanine nucleotide exchange
factor for Rho family proteins (21). Recent studies have
shown that Vav can induce Rac-1–mediated activation of the
MAP kinase JNK-1 (22). In a clinical context, the Wiskott-
Aldrich Syndrome immunodeficiency has been mapped to a
defect in expression of an effector protein for the GTPase
CDC42 (23).
Previous studies have shown that Fc
 
e
 
R1 induction of a
number of cytokine genes is sensitive to the imunosuppres-
sive drug cyclosporin A (CsA) (24). The CsA sensitivity of
cytokine gene induction reflects the importance of the CsA
target molecule, the calcium dependent phosphatase cal-
cineurin (CN), in this process. CN is critical for the regula-
tion of the nuclear factor of activated T cells (NFAT), a
transcription factor involved in the regulation of various
cytokine genes (25, 26). In addition to the role of calcium/
CN, a previous report has shown that Ras signals link the
Fc
 
e
 
R1 to regulation of the IL-5 cytokine gene (27). How-
ever, there is no description of Ras effector pathways in-
volved in coupling the Fc
 
e
 
R1 to nuclear events, or in de-
termining the repertoire of such targets for Ras signals. The
present report identifies the transcription factors Elk-1 and
NFAT as targets for Ras signals in mast cells. Moreover, we
explore the Ras effector pathways used to link the Fc
 
e
 
R1
to these targets. The data show that the Fc
 
e
 
R1 regulates
Elk-1 transactivation via a Ras/MEK-dependent pathway.
The Fc
 
e
 
R1 activation of Elk-1, described herein for Fc
 
e
 
R1
signaling, provides the paradigm for involvement of the
“classical” Ras/Raf-1/MEK cascade in coupling antigen
receptors to gene transcription. We also show that NFAT
in the context of the IL-4 promoter is another nuclear tar-
get for Ras signals downstream of the Fc
 
e
 
R1. However, in
contrast to Elk-1, Fc
 
e
 
R1 regulation of NFAT is accom-
plished by an effector pathway for Ras distinct from Raf-1/
MEK. The present study also provides the first evidence
that a member of the Rho family of GTPases, Rac-1, can
regulate Fc
 
e
 
R1 induction of NFAT. These data reveal the
complexity and efficacy of Ras and Rho family GTPases in
coupling antigen receptors to diverse nuclear events.
 
Materials and Methods
 
Reagents.
 
KLH-DNP conjugate, ionomycin calcium salt, CsA
and phorbol-12,13 dibutyrate were from Calbiochem (La Jolla,
CA). Monoclonal IgE anti-DNP was from Sigma Chemical Co.
(St. Louis, MO), as were all reagents for chloramphenicol acetyl
transferase (CAT) assays except 
 
14
 
C acetyl coenzyme A from Am-
ersham International (Buckinghamshire, England). MEK inhibi-
tor PD095089 was from New England Biolabs (Beverly, MA).
The PKC inhibitor Ro-318425 was a gift from Dr. David Wil-
liams (Roche Pharmaceuticals, Welwyn, UK). Anti-pan–Erk an-
tibody was from Affiniti (UK).
 
Cell Culture and Stimulation.
 
The rat basophilic leukemia cell
line RBL2H3 as maintained in DMEM supplemented with 10%
(vol/vol) heat-inactivated (56
 
8
 
C for 30 min) fetal bovine serum.
Only the adherent fraction of the cell cultures was passaged or
used in experiments. Cells were detached from culture substrate
using cell scrapers, washed once, and primed with 1 
 
m
 
g/ml IgE
anti-DNP in DMEM, 10% fetal bovine serum for 2 h at 37
 
8
 
C.
Receptor cross-linking was effected using 500 ng/ml KLH-DNP
conjugate (Calbiochem) at 37
 
8
 
C. Other stimuli were applied as
follows: 50 ng/ml PdBu, 500 ng/ml ionomycin.
 
Western Blotting.
 
Conditions for RBL2H3 lysis and Western
blotting were as described previously (10). Briefly, postnuclear ly-
sates were prepared, and cellular proteins were acetone precipi-
tated and then resolved by 15% SDS-PAGE. Proteins were trans-
ferred to polyvinyl difluoride membrane which was blocked in 5%
nonfat milk for 1 h at room temperature before probing with 1
 
m
 
g/ml anti-Erk (Affiniti). The membrane was washed three times
in PBS/0.02% Tween-20, and incubated with 0.5 
 
m
 
g/ml goat
anti–mouse horseradish peroxidase conjugate. After washing as
above, Erk bands were visualized by enhanced chemilumines-
cence (Amersham International).
 
Plasmids.
 
LexA OP.tk CAT comprises two copies of the
LexA reporter. In conjunction with the pEF-NLexA Elk-1C fu-
sion protein, its use has already been described (28). This system
involves the transfection of a reporter gene construct of a LexA
binding site upstream of the CAT reporter gene under a thymi-
dine kinase minimal promoter (LexA OP.tk CAT). A plasmid
encoding a fusion protein of the LexA DNA binding domain and
Elk-1 COOH-terminal region under a constitutive promoter is
cotransfected (pEF-NLexA Elk-1C). The LexA region of the fu-
sion protein binds constitutively to its site on the reporter gene
construct. Activation signals phosphorylate the Elk-1C region of
the fusion protein, leading to recruitment of transcriptional ma-
chinery and CAT gene induction. The IL-4 NFAT CAT reporter
was a gift of E. Serfling (Wurzburg University, Wurzburg, Germany)
and comprised a trimerized NFAT/AP-1 site derived from purine
box B of the murine IL-4 promoter (GATCCTGAGTTTAC-
ATTGGAAAATTTTATAGAGCGAGTTG). Plasmids encoding 
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signaling proteins were as follows: pEF-BOSv-HaRas (constitutively
active V12Ras), RSVN17Ras (dominant inhibitory Ras), and pEF-
dnRaf-1 (dominant inhibitory Raf-1, Raf-1 residues 1-257). The
active pEF-V12Rac, dominant inhibitory pEF-N17Rac, and ac-
tive pEF-V14Rho mutants have all been previously described (29).
The constitutively active membrane targeted pEF-Raf-1CAAX
was a gift of J. Downward (Imperial Cancer Research Fund).
Plasmid DNA was prepared by CsCl density gradient centrifuga-
tion.
 
Transient Transfection Assays Using CAT Reporter Gene Con-
structs.
 
Transient transfection was carried out using a Beckman
Gene-Pulser electroporation apparatus. RBL2H3 monolayer cells
were detached from the culture flask using a cell scraper, and re-
suspended at 2 
 
3
 
 10
 
7
 
 cells/0.6 ml DMEM 
 
1
 
 10% FCS at 37
 
8
 
C.
Cell were pulsed in 0.4 cm cuvettes (Beckman) at 310 V, 960 
 
m
 
F
before pooling, dilution in complete medium, and division at 1 ml/
well between wells of a 24-well tissue culture plate. Cells were al-
lowed to recover for 6 h at 37
 
8
 
C before priming and stimulation
as indicated.
For CAT reporter gene assays 5 
 
3
 
 10
 
6
 
 cells were lysed in 150 
 
m
 
l
buffer containing 0.65% (vol/vol) NP-40, 10 mM Tris, pH 8.0,
1 mM EDTA, and 150 mM NaCl for 15 min on ice. Lysates were
then transferred to a 68
 
8
 
C water bath for 10 min. Cell debris was
pelleted, and aliquots of lysate were removed to a fresh tube in an
assay volume of 100 
 
m
 
l to which 40 
 
m
 
l of a start solution contain-
ing 0.5 mM acetyl CoA, 5 mM chloramphenicol, 0.5 M Tris, pH
8.0, and 1 
 
m
 
l/point of 50 
 
m
 
Ci/ml 
 
14
 
C acetyl coenzyme A was
added. The assay was incubated for 16 h at 37
 
8
 
C before chloram-
phenicol was extracted using ethyl acetate. The amount of radio-
activity in the acetylated product and nonacetylated substrate for
each reaction was determined by liquid scintillation counting of
organic and aqueous phases, respectively. Results are expressed as
percentage conversion of chloramphenicol to the acetylated form.
 
Results
 
Elk-1 Transactivation Is Induced by the Fc
 
e
 
R1 and Phorbol
Esters, But Not by the Action of Calcium Ionophore.
 
The ef-
fects of various stimuli on Elk-1 activity in mast cells were
assessed using a CAT reporter gene assay for Elk-1 transac-
tivation. The data in Fig. 1 
 
a
 
 shows that antigenic cross-linking
of the Fc
 
e
 
R1 using KLH-DNP strongly induces Elk-1
transactivation in a dose-dependent manner. In addition,
the phorbol ester PdBu that directly activates PKC, induces
ninefold induction of Elk-1 transactivation over basal lev-
els. Fig. 1 
 
a
 
 also shows that elevation of intracellular cal-
cium levels using the ionophore Ionomycin is not sufficient
for Elk-1 activation. Stimulation by Fc
 
e
 
R1 or the phorbol
ester PdBu does not induce LexA OPtk.CAT activity in
the absence of a coexpressed LexA Elk-1C fusion protein
(Fig. 1 
 
b
 
).
Fc
 
e
 
R1 ligation is known to activate PKC, and previous
studies have established that PKC mediated signals are im-
 
Figure 1.
 
(
 
a
 
) Fc
 
e
 
R1 activation stimulates Elk-1 transactivation in mast
cells. 12 
 
m
 
g LexA OPtk.CAT and 6 
 
m
 
g LexA Elk-1C plasmids were used
per 1 
 
3
 
 10
 
7
 
 cells in electroporation at 310 V/960 
 
m
 
F. Cells were recov-
ered as described in Materials and Methods before stimulation for 16 h
with PdBu (50 ng/ml), Ionomycin (500 ng/ml) alone or in combination
(
 
P
 
1
 
I
 
), 
 
or IgE priming followed by antigenic cross-linking of the Fc
 
e
 
R1
with the indicated dose of KLH-DNP. Control cells (
 
NS
 
) were left un-
stimulated. (
 
b
 
) Stimulation of LexA OP.tk CAT activity is dependent on
the presence of the LexA Elk-1C fusion protein. 1 
 
3
 
 10
 
7
 
 cells per stimu-
lus were electroporated as described with 12 
 
m
 
g LexA OPtk.CAT alone
or in combination with 6 
 
m
 
g LexA Elk-1C. Cells were recovered, and
then stimulated for 16 h as described above. (
 
c
 
) Fc
 
e
 
R1 activation of Elk-1
is not PKC-dependent. Cells were transfected with the Elk-1 reporter
system as described, and recovered for 6 h. Preincubation with either 1
 
m
 
M Ro-318425 or DMSO carrier was 30 min at 37
 
8
 
C before stimulation
with either PdBu (50 ng/ml) or KLH-DNP (250 ng/ml). 
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portant for Fc
 
e
 
R1 induction of mast cell degranulation.
PKC activation is therefore a candidate mechanism for
Fc
 
e
 
R1 induction of Elk-1. We used a broad-spectrum in-
hibitor of PKC isozymes, Ro-318425 (30), to assay the
contribution of PKC to Elk-1 induction by the Fc
 
e
 
R1.
Ro-318425 inhibits the activity of the major PKC iso-
zymes shown to translocate to the plasma membrane fol-
lowing Fc
 
e
 
R1 ligation. The data in Fig. 1 
 
c
 
 show that a 500
nM dose of Ro-318425 inhibits PdBu activation of Elk-1
by 85%. In contrast, FceR1 stimulation can potently in-
duce Elk-1 transactivation, despite the presence of Ro-
318425.
The data in Fig. 1 a demonstrate that signals derived from
the FceR1 regulate the transcriptional activity of Elk-1.
The insensitivity of FceR1 stimulation of Elk-1 to the
PKC inhibitor Ro-318425 suggests that PKC-mediated
signals are not essential for Elk-1 regulation by the FceR1.
Raising of intracellular calcium levels by ionomycin treat-
ment or the mimicking of this effect by the cotransfection
of an activated mutant of the calcium-dependent phos-
phatase calcineurin (data not shown) did not induce Elk-1
activity. Hence, we investigated candidate noncalcium/
PKC pathways for Elk-1 activation.
Elk-1 Activation in Mast Cells Is Induced by Constitutively
Active Mutants of Ras and Raf-1. Elk-1 could be a target
for a kinase cascade initiated by Ras. The prototypical ki-
nase cascade transducing Ras signals is the Raf-1/MEK/
Erk pathway, and there is a precedent for Elk-1 activation
via this mechanism in the fibroblast (31). To explore the
role of Ras and Raf-1 signals in Elk-1 activation in mast
cells, we examined the effects of activated Ras and Raf-1
mutants on Elk-1 activity in mast cells. The Raf-1 con-
struct used here is a fusion protein of Raf-1 with a CAAX
box motif that targets Raf-1 to the plasma membrane, ren-
dering the exogenously expressed Raf-1 constitutively ac-
tive (32). In these experiments, plasmids bearing the indi-
cated mutants were cotransfected with the LexA Elk-1C
fusion protein expression plasmid and the LexA OP.tkCAT
reporter gene. The data in Fig. 2 a show that activated
forms of both Ras and a Ras effector, Raf-1, are capable of
inducing Elk-1 transactivation in RBL2H3 cells in the ab-
sence of other stimuli.
In additional experiments we investigated whether FceR1
induction of Elk-1 is dependent on the activation of a Ras
cascade using dominant inhibitory mutants. The N17 mu-
tant of Ras acts to sequester guanine nucleotide exchange
factors from endogenous pools of the GTPase, and main-
tains Ras in its GDP-bound, inactive state. The dominant
inhibitory (dn) Raf-1 mutant has the COOH-terminal ki-
nase domain truncated; this mutant binds to activated
Ras.GTP and prevents its interaction with effector pro-
teins. Figs. 2 b and c show the effect of dn mutants of Ras
and Raf-1 on FceR1 induction of Elk-1 transactivation.
FceR1 induction of Elk-1 activity is inhibited by expres-
sion of either N17Ras or dnRaf-1, in a manner that is dose
dependent on the amount of dominant negative plasmid
used for cotransfection. At 20 mg cotransfected N17Ras or
Figure 2. (a) Activated Ras or Raf are sufficient for Elk-1 activation in
mast cells. 1 3 107 cells per point were transfected with either the Elk-1
reporter system alone or in combination with 10 mg pEF-V12Ras or 10 mg
pEF Raf-CAAX. Cells transfected with activated mutants were left un-
stimulated, while control cells were exposed to either 50 ng/ml PdBu or
1 mg/ml IgE/500ng/ml KLH-DNP in the concentrations indicated above.
(b and c) FceR1 activation of Elk-1 is dependent on Ras. 1 3 107 cells per
point were transfected with either the Elk-1 reporter system alone (con-
trol), or in combination with 15 mg of either RSV N17Ras or pEF dn
Raf-1. Cells were recovered and left unstimulated (NS) or exposed to
IgE/KLH-DNP as described.47 Turner et al.
dnRaf-1, the percentage inhibitions of FceR1 induction of
Elk-1 transactivation were 74 and 79%, respectively. The
sensitivity of FceR1 induction of Elk-1 to dominant in-
hibitory mutants of both Ras and Raf-1 suggests that the
“classical” pathway for MAP kinase stimulation is involved in
Elk-1 activation in RBL2H3 cells. In this pathway, Ras.GTP
induces membrane targeting and activation of Raf-1, that
acts subsequently on Erk members of the MAP kinase fam-
ily via the Erk-activating kinase MEK. However, the dn
Raf-1 mutant not only prevents interactions between acti-
vated Ras and endogenous Raf-1, but also blocks Ras
binding to other effector molecules. Thus, to explore the
role of the MEK/Erk2 pathway in Elk-1 regulation more
directly, we used PD098059, an inhibitor of the Erk2 stim-
ulatory kinase, the MAP kinase kinase MEK.
The specificity of PD098059 as a MEK inhibitor has
been previously described (33). Nevertheless, in initial ex-
periments we verified that PD098059 was an effective
MEK inhibitor in RBL2H3 cells. The phosphorylation of
Erk by MEK results in decreased electrophoretic mobility
of Erk in SDS-PAGE. Fig. 3 a shows an Erk mobility shift
assay visualized by pan-Erk Western blot. In control cells
(left), PdBu or FceR1 stimulation cause the appearance of
an hyperphosphorylated Erk population. The application of
25 mM PD098059 (right) efficiently inhibits the activation
of Erk by MEK in mast cells. Accordingly, we examined
the effect of PD098059 on induction of Elk-1 transactiva-
tion in mast cells. As shown in Fig. 3 b, the activation of
Elk-1 induced by cotransfection of Raf-CAAX and V12Ras
constructs is inhibited by PD098059. Hence, these mutants
are indeed reflecting the use of a Raf-1/Erk pathway to
target Elk-1. Fig. 3 c shows that the induction of Elk-1
transactivation by both PdBu and FceR1 cross-linking is
inhibited by PD098059 in a dose-dependent manner. These
data confirm that the Raf-1/MEK cascade is the critical
Ras effector pathway for FceR1 activation of Elk-1.
NFAT Is a Target for a Ras Effector Pathways Distinct from
Raf-1/MEK in the Mast Cell. FceR1 stimulation results in
the activation of cytokine genes, the products of which
play important roles both locally in inflammation and sys-
temically. Transcription factors of the NFAT family are
important for cytokine gene induction in a variety of cells
and a well characterized target for NFAT family proteins in
an activated mast cell is the gene for IL-4 (25). FceR1 trig-
gering has been shown to induce NFAT DNA binding ac-
Figure 3. (a) PD098059 inhibits MEK activation of Erk in mast cells. 1 3
106 RBL2H3 per point were incubated for 30 min at 378C with DMSO
(control) or 25 mM PD098059. Stimulations were for 10 min with either
50 ng/ml PdBu or, after priming with IgE anti DNP, 10 min 500 ng/ml
KLH-DNP. Western blotting for Erk was carried out as described in Ma-
terials and Methods. (b) Induction of Elk-1 via activated Ras and Raf-1 is
sensitive to inhibition of MEK. 1 3 107 cells per point were transfected
with either the Elk-1 reporter system alone, or in combination with 10 mg
pEF V12Ras or 10 mg pEF Raf-CAAX. Control cells were left unstimu-
lated (NS) or exposed to IgE/KLH-DNP. Cotransfected cells were left
unstimulated. Preincubation with 25 mM PD098059 or DMSO was for
30 min before stimulation. (c) Induction of Elk-1 activity by FceR1 or
PdBu is sensitive to inhibition of MEK. 1 3 107 cells per point were
transfected with the Elk-1 reporter system and recovered for 6 h. Cells
were preincubated for 30 min with either DMSO or the indicated con-
centrations of PD098059. Cells were left unstimulated (NS), exposed to
IgE/KLH-DNP, or PdBu as described.48 Ras Effector Pathways in Mast Cells
tivity (26), and we investigated FceR1 mechanisms for
NFAT induction in mast cells using a reporter construct
comprising a trimerized NFAT site derived from the mu-
rine IL-4 promoter.
Fig. 4 a shows that FceR1 cross-linking induces IL-4
NFAT activity in a manner dose dependent on antigen.
The PKC inhibitor Ro-318425 did not affect the FceR1
activation of NFAT (data not shown). To address whether
there is a role for Ras in the FceR1 regulation of NFAT,
we cotransfected active and dominant inhibitory Ras mu-
tants with the IL-4 NFAT-CAT reporter gene. Expres-
sion of active V12Ras induced a weak increase in the basal
activity of the NFAT reporter gene, and robustly potenti-
ated FceR1 induction of NFAT. Conversely, expression of
N17Ras inhibited the NFAT response to FceR1 (Fig. 4 b).
Hence, cotransfected activated Ras (V12Ras) causes a po-
tentiation of FceR1 activation of IL-4 NFAT that potently
increases the sensitivity of NFAT responses to antigen. The
presence of N17Ras consistently inhibits the antigen dose
response for IL-4 NFAT CAT induction to half-maximal
levels, and supresses the antigen sensitivity of the mast cells
for NFAT activation.
Raf-1 was a key effector for activation of Elk-1 in mast
cells and expression of membrane targeted, and hence
active, Raf-1 (Raf-CAAX) could mimic the effects of
V12Ras and potently stimulate Elk-1 transcriptional activ-
ity. However, Fig. 4 b shows that expression of Raf-CAAX
cannot substitute for V12Ras to induce NFAT transcrip-
Figure 4. (a) FceR1 cross-linking induces IL-4 NFAT CAT activity in
a dose-dependent manner. 1 3 107 cells per point were transfected with
15 mg IL-4 NFAT CAT reporter. Cells were recovered for 6 h before
IgE priming and stimulation with the indicated concentrations of KLH-
DNP. (b) FceR1 stimulation of IL-4 NFAT is potentiated by active
V12Ras, but not Raf-CAAX, and is inhibited by the presence of domi-
nant negative N17Ras. 1 3 107 cells per point were transfected with 15 mg
IL-4 NFAT CAT reporter alone (solid line, filled squares), or in combina-
tion with 15 mg active V12Ras (solid line, open circles), 15 mg dominant in-
hibitory N17Ras (broken line, filled diamonds), or 15 mg Raf-CAAX (broken
line, open triangles). Cells were recovered for 6 h before IgE priming, and then
stimulation with the indicated concentrations of KLH-DNP. (c) FceR1
stimulation of IL-4 NFAT CAT activity is insensitive to PD098059. 1 3
107 cells per point were transfected with 15 mg IL-4 NFAT CAT reporter
alone, and recovered for 6 h. Cells were preincubated for 30 min with ei-
ther DMSO or the indicated concentrations of PD098059. Cells were left
unstimulated (NS), exposed to IgE/KLH-DNP, or treated with 50 ng/ml
PdBu and 500 ng/ml ionomycin.49 Turner et al.
tional activity. These data prompted us to investigate the
effect of inhibiting the Raf-1/MEK pathway using PD098059
on NFAT transcriptional activity. Fig. 4 c shows that the
activation of IL-4 NFAT CAT by the FceR1 is insensitive
to the application of PD098059. Hence, in contrast to Elk-1,
the critical Ras effector pathway for NFAT regulation in
mast cells cannot be Raf-1/Erk.
The Rho Family GTPase Rac-1 Regulates the NFAT Re-
sponse to FceR1 Stimulation in Mast Cells. The Rho fam-
ily GTPase Rac-1 has been shown to play a role in Ras
regulation of fibroblast transformation (19) and in T cell
antigen receptor regulation of NFAT (34). We therefore
investigated the effects of Rho family GTPases in FceR1
signaling to NFAT. Active mutants of Rac-1 and Rho
(V12Rac and V14Rho, respectively) were used to assay
whether these GTPases can regulate IL-4 NFAT activation
in the mast cell. Fig. 5 a shows that expression of the active
V12Rac mutant induced an increase in the basal activity of
the NFAT reporter gene, and highly potentiated the
FceR1 activation of IL-4 NFAT. To demonstrate the spec-
ificity of this effect, we showed that an activated V14Rho
had no discernable potentiating effect on IL-4 NFAT in-
duction (Fig. 5 a).
The ability of active Rac-1 to potentiate FceR1/NFAT
responses shows that this GTPase has the potential to regu-
late NFAT activity in mast cells. To examine whether
Rac-1 actually plays a role in the NFAT response to FceR1
stimulation, we cotransfected the NFAT reporter gene
with an inhibitory mutant of Rac-1, N17Rac. The data in
Fig. 5 a show that expression of N17Rac had a marked in-
hibitory effect on FceR1 induction of NFAT. As a speci-
ficity control, we examined the effect of N17Rac on
FceR1 activation of Elk-1 transcription. Fig. 5 b shows that
FceR1 induction of Elk-1 is insensitive to the presence of
N17Rac; therefore, we have demonstrated a specific require-
ment for Rac-1 activity in FceR1 regulation of NFAT.
Figure 5. (a) FceR1 stimulation of IL-4 NFAT is potentiated by active
V12Rac, and is inhibited by the presence of dominant negative N17Rac.
1 3 107 cells per point were transfected with 15 mg IL-4 NFAT CAT re-
porter alone (solid line, filled squares), or in combination with 15 mg active
V12Rac (broken line, filled diamonds), 15 mg dominant inhibitory N17Rac
(solid line, open circles), or 15 mg active V14Rho (broken line, open triangles).
Cells were recovered for 6 h before IgE priming and stimulation with the
indicated concentrations of KLH-DNP. (b) FceR1 stimulation of Elk-1
activity, a Raf-1/MEK-dependent process, is insensitive to N17Rac ex-
pression. 1 3 107 cells per point were transfected with either the Elk-1 re-
porter system alone (control), or in combination with 15 mg of pEFN17Rac.
Cells were recovered and left unstimulated (NS), or exposed to IgE/
KLH-DNP as described. (c) Stimulation of NFAT by the FceR1 alone or
in concert with V12Rac is sensitive to CsA. 1 3 107 cells per point were
transfected with 15 mg IL-4 NFAT CAT reporter alone (solid line, open
squares), or in combination with 15 mg active V12Rac (broken line, filled di-
amonds). Cells were recovered, primed with IgE anti-DNP, and preincu-
bated for 30 min with either vehicle (control) or the indicated dose of CsA
before FceR1 stimulation as described.50 Ras Effector Pathways in Mast Cells
Induction of NFAT trancriptional activity in mast cells is
dependent on the calcium/calcineurin pathway, and is
therefore sensitive to inhibition via the immunosuppressive
drug CsA (25). The data in Fig. 5 c show that the FceR1
induction of NFAT is also sensitive to the action of CsA in
a dose-dependent manner. Expression of the activated
V12Rac mutant, which potentiates FceR1 induction of
NFAT, was unable to reverse the inhibition of the response
observed with CsA. These data indicate that FceR1 induc-
tion of NFAT requires at least the convergent action of
Rac and CN pathways.
Discussion
The data herein show that the FceR1 activation of Ras
and its effector pathways allow receptor regulation of the
transcription factors Elk-1 and NFAT. The diversity of its
effector pathways enables Ras to act in a critical position to
direct activation of various nuclear targets. We have shown
that Ras signals are thus necessary and sufficient for FceR1
transcriptional activation of Elk-1, a transcription factor
important in the context of the serum response element
which is a regulatory component of immediate early gene
promoters (31). Ras signals also play a role in FceR1 regu-
lation of NFAT complexes, although they are not sufficent
for this response. In this report we have also identified
NFAT as a target for Rac-1 signaling pathways in mast
cells. Expression of active Rac-1 protein dramatically po-
tentiates FceR1 induction of NFAT, whereas expression of
an inhibitory Rac-1 mutant severely abrogates the NFAT
response to FceR1 stimulation. These data place the GTP-
ases Ras and Rac-1 in a critical position regulating the nu-
clear component of mast cell end function.
The SRE is responsible for regulation of immediate early
genes such as c-fos and egr-1, and has been shown to be a
convergence point for varied signaling pathways including
the Ras/MEK pathway in fibroblasts (35, 28). Extensive
studies have shown that transcriptional activation of Elk-1
is dependent on its COOH-terminal phosphorylation by
members of the MAP kinase family such as Erk-1/2, the
Jun (stress-activated) kinase JNK, and the p38 kinase (28,
36). Despite the potential for Elk-1 to be targeted by mul-
tiple MAP kinases, the data herein show that the Ras effec-
tor pathway involved in FceR1 regulation of Elk-1 abso-
lutely requires the activity of the Erk-activating kinase
MEK, acting downstream of Ras and its effector Raf-1.
These data show that the Ras/Raf-1/MEK pathway has a
dominant role in FceR1 regulation of Elk-1, reflecting
clear parallels between Elk-1 activation following antigen
receptor ligation and growth factor stimulation of fibro-
blasts.
NFAT family members form regulatory complexes which
bind cytokine gene promoters (37). Initially described as
critical for IL-2 production in T cells, NFAT has also been
implicated in transcriptional activation of the genes for IL-4,
GM-CSF, and TNFa. NFAT comprises a cytoplasmic
component which translocates to the nuclei of stimulated
cells and complexes with an inducible nuclear component.
The former component is encoded by an extensive gene
family including NFATp, NFATc, NFAT-3, and NFAT-4/x.
The latter is composed of AP-1 family members, e.g., Fos/Jun.
NFATp is a crucial transcription factor for regulation of the
IL-4 gene in the T cell (38), and is implicated in transcrip-
tional activation of the IL-4 gene in mast cells (25). IL-4
produced by mast cells after FceR1 cross-linking is thought
to play an important role in the generation of a sustained
inflammatory response. Locally, a pulse of mast cell IL-4
stimulates T cells into sustained IL-4 production and subse-
quent inflammatory cell infiltration. By feeding back on B
cells to promote antigen specific IgE production, mast cell–
derived IL-4 contributes to the sustained responsiveness of
mast cells themselves to antigen/allergen.
Previous studies in T cells have shown that transcrip-
tional activity of the NFAT complex required for IL-2
gene induction is dependent on the concerted action of
Ras and calcium/calcineurin signaling pathways (39). More-
over, previous data from our laboratory has shown that
multiple Ras effector pathways converge on NFAT in the
context of the IL-2 promoter (34). The Raf-1/MEK path-
way is one component of TCR induction of NFAT, but
there is also a contribution from signals regulated by the
GTPase Rac-1 (34). In the context of the activated mast
cell, one target for NFAT is the IL-4 gene promoter. We
have found that Ras signals are an absolute requirement for
FceR1 regulation of a reporter construct driven by a region
of the IL-4 promoter 270 base pairs upstream of the tran-
scriptional start site (Turner, H., and D.A. Cantrell, unpub-
lished observation). The clear implication of this finding is
that the IL-4 promoter contains targets for Ras signaling
pathways, one of which we establish as NFAT.
Calcium/calcineurin signals are known to be critical for
NFAT responses; IL-4 NFAT CAT activity can be strongly
induced by an activated mutant of calcineurin or by iono-
phore treatment (Turner, H., and D.A. Cantrell, unpub-
lished observations). The role of calcium signals in NFAT
regulation in the T cell is to induce nuclear translocation of
NFAT protein (37, 40, 41). The present data show that in
addition to a requirement for calcium/calcineurin, Ras and
Rac-1 signaling pathways are important for FceR1 induc-
tion of IL-4 NFAT. While expression of activated Ras
could potentiate FceR1 induction of NFAT, this effect
could not be mimicked by stimulation of the Raf-1/MEK
pathway using Raf-CAAX. Furthermore, inhibition of
MEK/Erk2 activity does not affect FceR1 activation of
NFAT. Hence, we are able to exclude the “classical” Ras/
Raf-1/MEK cascade. In comparison with the data in the T
cell system, we also observe in mast cells that NFAT inte-
grates multiple signals. In the mast cell, as in the T cell,
there is a requirement for both calcium/calcineurin and
Rac-1 signals in antigen receptor regulation of NFAT.
However, the nature of the Ras signal, which is also re-
quired, differs between the two systems. In the mast cell,
there is no requirement for Raf-1/MEK activity, while in
the T cell, NFAT is regulated by this and another unchar-
acterized Ras effector pathway (34).
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quire the activity of other GTPases; notably, Ras mediated
transformation of fibroblasts requires signaling pathways
mediated by Rac-1 and RhoA (18, 19). The data herein
show that IL-4 NFAT activation in mast cells requires the
function of Rac-1. The recognition that Rac-1 may play a
pivotal role in NFAT responses raises the issue of the iden-
tity of Rac-1 effector pathways in mast cells. Proteins that
can bind directly to GTP-bound active Rac-1 include mem-
bers of the p21-associated kinase serine/threonine kinase
family (42) and the ribosomal p70S6 kinase (43). Rac-1 has
also been shown to activate the MAP kinase family mem-
bers JNK-1 and p38 (44), making these candidate kinases
for transduction of the Rac-1 signal leading to NFAT acti-
vation in mast cells.
There is an inhibitor of the p38 kinase available SB203580
(45) which does not modulate NFAT responses to FceR1
activation (Turner, H., and D.A. Cantrell, unpublished ob-
servations). The immunosupressant Rapamycin which in-
hibits p70S6 kinase also does not inhibit NFAT activation,
excluding a role for this kinase in NFAT responses. Hence,
it is unlikely that these enzymes are responsible for Rac-1
activation of NFAT. We have observed in preliminary ex-
periments that the FceR1 activates the MAP kinase JNK-1
(Turner, H., and D.A. Cantrell, unpublished observation,
and P. Bauer, personal communication). However, there
are no small molecule inhibitors of JNK-1 pathways analo-
gous to the PD098059 MEK inhibitor or the SB203580
p38 inhibitor that can be used to probe the cellular role of
JNK-1 in NFAT responses. Therefore, the role of Rac-1 in
coupling the FceR1 to JNK-1 has yet to be examined.
Moreover, JNK-1 is by no means the sole remaining candi-
date for a Rac-1 effector after the elimination of ERK, p38
and p70S6 kinase. There is now a burgeoning body of
work on novel Rac-1 effectors including members of the
p21-associated kinase family and the cytoskeletal regulatory
protein POR-1 (42, 46).
The requirement for both Ras and Rac-1 function for
FceR1 activation of NFAT in mast cells is consistent with a
model where Rac-1 is part of a separate FceR1 signaling
pathway that converges with Ras signals on IL-4 NFAT
to fully activate the transcription factor complex. Never-
theless, it is equally possible to envisage a mechanism in
which Rac-1 acts as a downstream effector for Ras. For
example, Vav is a putative Rac-1/RhoA guanine nucle-
otide exchange protein (21) that is tyrosine phosphorylated
in response to FceR1 ligation (20), and is able to stimulate
Rac-1–mediated JNK-1 activation in fibroblasts (22). Vav
would thus be a candidate molecule for coupling the FceR1
to Rac-1 responses. This model is analogous to the links
between Ras and Rac-1 that have been documented in fi-
broblasts where Rac-1 couples Ras to the signaling pathways
that control rearrangements of the actin cytoskeleton (47).
It is difficult to resolve these various possibilities (sum-
marized in Fig. 6), and they are not mutually exclusive; Ras
and Rac-1 may integrate signals from multiple inputs in the
mast cell. This may be true both in terms of multiple intra-
cellular signals generated by antigen receptor ligation, and
in terms of reactivity to different extracellular stimuli. Cer-
tainly, Ras is not only activated by antigen receptor trigger-
ing in mast cells, but can be activated by cytokines such as
IL-3 and GM-CSF (48). Activation of Ras-stimulatory
pathways by integrins, which are likely to be involved in
mast cell adherence to a tissue substratum, has also been
documented (49). It is reasonable to expect that during the
early course of an inflammatory response, mast cells would
be exposed to Ras-activating cytokines such as IL-3 and
GM-CSF produced by antigen activated T cells. The effect
of Ras activation on IL-4 NFAT activity is essentially that
of altering the antigen receptor dose response threshold.
Hence, exposure of mast cells to Ras-activating cytokines
can be viewed as an important priming step which increases
the responsiveness of mast cells to a given antigen dose.
Figure 6. Putative mechanism for FceR1 action on transcription factor
targets in mast cells. Ras signals through the Raf-1/MEK pathway are
necessary and sufficient for Elk-1 activation. In contrast, the NFAT com-
plex integrates multiple signals from the FceR1. Calcium signals induce nu-
clear translocation of NFAT protein. Ras and Rac-1 GTPases are also impli-
cated in FceR1 activation of NFAT, acting either in parallel or in series.
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